Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Total Current Liabilities (2022 - 2025)

BioXcel Therapeutics has reported Total Current Liabilities over the past 4 years, most recently at $53.9 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $53.9 million for Q4 2025, up 142.55% from a year ago — trailing twelve months through Dec 2025 was $53.9 million (up 142.55% YoY), and the annual figure for FY2025 was $53.9 million, up 142.55%.
  • Total Current Liabilities for Q4 2025 was $53.9 million at BioXcel Therapeutics, up from $37.8 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for BTAI hit a ceiling of $53.9 million in Q4 2025 and a floor of $16.0 million in Q1 2022.
  • Median Total Current Liabilities over the past 4 years was $28.0 million (2023), compared with a mean of $30.0 million.
  • Biggest five-year swings in Total Current Liabilities: tumbled 35.15% in 2024 and later soared 142.55% in 2025.
  • BioXcel Therapeutics' Total Current Liabilities stood at $32.9 million in 2022, then fell by 17.12% to $27.3 million in 2023, then dropped by 18.46% to $22.2 million in 2024, then soared by 142.55% to $53.9 million in 2025.
  • The last three reported values for Total Current Liabilities were $53.9 million (Q4 2025), $37.8 million (Q3 2025), and $33.4 million (Q2 2025) per Business Quant data.